Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 3832

1.

Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.

Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ.

Am J Surg Pathol. 2009 Aug;33(8):1125-36. doi: 10.1097/PAS.0b013e31819e986a.

PMID:
19440148
2.

Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.

Rabban JT, Crawford B, Chen LM, Powell CB, Zaloudek CJ.

Am J Surg Pathol. 2009 Jan;33(1):111-9. doi: 10.1097/PAS.0b013e31817d74a7.

PMID:
18830124
3.

Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol.

Rabban JT, Krasik E, Chen LM, Powell CB, Crawford B, Zaloudek CJ.

Am J Surg Pathol. 2009 Dec;33(12):1878-85. doi: 10.1097/PAS.0b013e3181bc6059.

PMID:
19898224
4.

Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.

Powell CB, Chen LM, McLennan J, Crawford B, Zaloudek C, Rabban JT, Moore DH, Ziegler J.

Int J Gynecol Cancer. 2011 Jul;21(5):846-51. doi: 10.1097/IGC.0b013e31821bc7e3.

PMID:
21670699
5.

Pathologic findings in prophylactic oophorectomy specimens in high-risk women.

Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P.

Gynecol Oncol. 2002 Oct;87(1):52-6.

PMID:
12468342
6.

Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.

Rebbeck TR, Kauff ND, Domchek SM.

J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13.

7.

Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.

Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM.

Am J Obstet Gynecol. 2006 Jun;194(6):1702-9.

PMID:
16731090
8.

Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.

Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, Komaromy M, Beattie M, Ziegler J.

J Clin Oncol. 2005 Jan 1;23(1):127-32.

9.

Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.

Gabriel CA, Tigges-Cardwell J, Stopfer J, Erlichman J, Nathanson K, Domchek SM.

Fam Cancer. 2009;8(1):23-8. doi: 10.1007/s10689-008-9208-6. Epub 2008 Aug 29.

PMID:
18758995
11.
12.
13.

The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy.

Eitan R, Soslow R, Lin O, Kauff ND, Liu L, Barakat RR, Chi DS.

Gynecol Oncol. 2006 Aug;102(2):315-8. Epub 2006 Jan 23.

PMID:
16430946
14.

Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.

Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ.

Eur J Cancer. 2013 Jan;49(1):132-41. doi: 10.1016/j.ejca.2012.07.021. Epub 2012 Aug 21.

PMID:
22921157
15.

Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.

Kauff ND, Barakat RR.

J Clin Oncol. 2007 Jul 10;25(20):2921-7. Review.

PMID:
17617523
16.

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K.

N Engl J Med. 2002 May 23;346(21):1609-15. Epub 2002 May 20.

17.

Diathermy-induced injury may affect detection of occult tubal lesions at risk-reducing salpingo-oophorectomy.

Manchanda R, Silvanto A, Abdelraheim A, Burnell M, Johnson M, Saridogan E, Rosenthal AN, Brunell C, Aslam N, Vashisht A, Pandis G, Jacobs I, Menon U, Benjamin E.

Int J Gynecol Cancer. 2012 Jun;22(5):881-8. doi: 10.1097/IGC.0b013e31824b4093.

PMID:
22572844
18.

Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.

Manchanda R, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, Burnell M, Side L, Gessler S, Saridogan E, Oram D, Jacobs I, Menon U.

BJOG. 2011 Jun;118(7):814-24. doi: 10.1111/j.1471-0528.2011.02920.x. Epub 2011 Mar 10.

19.

Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.

Paley PJ, Swisher EM, Garcia RL, Agoff SN, Greer BE, Peters KL, Goff BA.

Gynecol Oncol. 2001 Feb;80(2):176-80.

PMID:
11161856
20.

Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.

Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J, Ellis N, Hensley M, Boyd J, Borgen P, Norton L, Offit K.

J Clin Oncol. 2002 Mar 1;20(5):1260-8.

PMID:
11870168
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk